MOORE JOHN R
General Counsel
MOORE JOHN R has filed 1 SEC Form 4 filing (6 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Aug 14, 2026.
On the most recent filing, MOORE JOHN R is listed as General Counsel at Edgewise Therapeutics, Inc. Inside the rolling window, MOORE JOHN R reported no open-market purchases and 1 open-market sale totaling $220K in EWTX.
Companies traded
Other insiders at EWTX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$220K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has MOORE JOHN R made?
MOORE JOHN R has filed 1 SEC Form 4 filing (6 transaction rows) across 1 company since 2026.
Which companies does MOORE JOHN R trade?
MOORE JOHN R has filed SEC Form 4 disclosures for 1 company, including EWTX.
When was MOORE JOHN R's most recent SEC Form 4 filing?
MOORE JOHN R's most recent SEC Form 4 filing on Tracefour is dated Aug 14, 2026.
What is MOORE JOHN R's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, MOORE JOHN R is listed as General Counsel.
What is MOORE JOHN R's total buy and sell value in the current window?
Inside the rolling retention window, MOORE JOHN R bought $0 and sold $220K based on SEC Form 4 filings.
What was MOORE JOHN R's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 5,016 EWTX shares on 2026-08-12, worth $220K, per SEC Form 4 filings.